Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.

Ruscito I, Darb-Esfahani S, Kulbe H, Bellati F, Zizzari IG, Rahimi Koshkaki H, Napoletano C, Caserta D, Rughetti A, Kessler M, Sehouli J, Nuti M, Braicu EI.

Gynecol Oncol. 2018 May 10. pii: S0090-8258(18)30892-8. doi: 10.1016/j.ygyno.2018.05.006. [Epub ahead of print]

PMID:
29753392
2.

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.

Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M.

Cancer Immunol Res. 2018 Apr 26. doi: 10.1158/2326-6066.CIR-17-0594. [Epub ahead of print]

PMID:
29700053
3.

Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets.

Ruscito I, Braicu EI, Gasparri ML, Zizzari IG.

Biomed Res Int. 2018 Mar 1;2018:6532019. doi: 10.1155/2018/6532019. eCollection 2018. No abstract available.

4.

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.

Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S.

Neoplasia. 2018 Mar;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. Epub 2018 Feb 22.

5.

PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?

Gasparri ML, Bardhi E, Ruscito I, Papadia A, Farooqi AA, Marchetti C, Bogani G, Ceccacci I, Mueller MD, Benedetti Panici P.

Geburtshilfe Frauenheilkd. 2017 Oct;77(10):1095-1103. doi: 10.1055/s-0043-118907. Epub 2017 Oct 26.

6.

Tumor-Derived Microvesicles Modulate Antigen Cross-Processing via Reactive Oxygen Species-Mediated Alkalinization of Phagosomal Compartment in Dendritic Cells.

Battisti F, Napoletano C, Rahimi Koshkaki H, Belleudi F, Zizzari IG, Ruscito I, Palchetti S, Bellati F, Benedetti Panici P, Torrisi MR, Caracciolo G, Altieri F, Nuti M, Rughetti A.

Front Immunol. 2017 Sep 25;8:1179. doi: 10.3389/fimmu.2017.01179. eCollection 2017.

7.

Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.

Sun T, Ruscito I, Dimitrova D, Chekerov R, Kulbe H, Baron U, Blanchard V, Panici PB, Darb-Esfahani S, Sehouli J, Olek S, Braicu EI.

Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665. doi: 10.1097/IGC.0000000000001071.

PMID:
28691938
8.

The Efficacy of Fibrin Sealant Patches in Reducing the Incidence of Lymphatic Morbidity After Radical Lymphadenectomy: A Meta-Analysis.

Gasparri ML, Ruscito I, Bolla D, Benedetti Panici P, Mueller MD, Papadia A.

Int J Gynecol Cancer. 2017 Jul;27(6):1283-1292. doi: 10.1097/IGC.0000000000001051.

PMID:
28640177
9.

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.

Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Ganapathi RN, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.

Eur J Cancer. 2017 Jul;79:214-225. doi: 10.1016/j.ejca.2017.04.016. Epub 2017 May 16.

PMID:
28525846
10.

Beyond circulating microRNA biomarkers: Urinary microRNAs in ovarian and breast cancer.

Gasparri ML, Casorelli A, Bardhi E, Besharat AR, Savone D, Ruscito I, Farooqi AA, Papadia A, Mueller MD, Ferretti E, Benedetti Panici P.

Tumour Biol. 2017 May;39(5):1010428317695525. doi: 10.1177/1010428317695525. Review.

11.

Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells.

Napoletano C, Bellati F, Ruscito I, Pernice M, Zizzari IG, Caponnetto S, Tomao F, Frigerio L, Liberati M, Rughetti A, Caserta D, Panici PB, Nuti M.

Anticancer Res. 2016 Oct;36(10):5109-5116.

PMID:
27798870
12.

Beyond the beyond: first case of 9 cytoreductive surgeries in a long-surviving ovarian cancer patient: case report.

Salerno L, Marchetti C, Bevilacqua E, Musella A, Riganelli L, Ruscito I, Perniola G, Muzii L, Benedetti Panici P.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000427.

PMID:
26391759
13.
14.

Effects of Neoadjuvant Chemotherapy Plus Radical Surgery as Front Line Treatment Strategy in Patients Affected by FIGO Stage III Cervical Cancer.

Di Donato V, Schiavi MC, Ruscito I, Visentin VS, Palaia I, Marchetti C, Fischetti M, Monti M, Muzii L, Benedetti Panici P.

Ann Surg Oncol. 2016 Dec;23(Suppl 5):841-849. Epub 2016 Sep 27.

PMID:
27678502
15.

Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes-A Meta-Analysis.

Ruscito I, Gasparri ML, Braicu EI, Bellati F, Raio L, Sehouli J, Mueller MD, Panici PB, Papadia A.

Ann Surg Oncol. 2016 Oct;23(11):3749-3756. doi: 10.1245/s10434-016-5236-x. Epub 2016 May 9. Review.

PMID:
27160526
16.

Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.

Antonilli M, Rahimi H, Visconti V, Napoletano C, Ruscito I, Zizzari IG, Caponnetto S, Barchiesi G, Iadarola R, Pierelli L, Rughetti A, Bellati F, Panici PB, Nuti M.

Int J Oncol. 2016 Apr;48(4):1369-78. doi: 10.3892/ijo.2016.3386. Epub 2016 Feb 8.

17.

Cediranib in ovarian cancer: state of the art and future perspectives.

Ruscito I, Gasparri ML, Marchetti C, De Medici C, Bracchi C, Palaia I, Imboden S, Mueller MD, Papadia A, Muzii L, Panici PB.

Tumour Biol. 2016 Mar;37(3):2833-9. doi: 10.1007/s13277-015-4781-4. Epub 2016 Jan 11. Review.

PMID:
26753963
18.

PARP inhibition: A promising therapeutic target in ovarian cancer.

Musella A, Marchetti C, Gasparri ML, Salerno L, Casorelli A, Domenici L, Imperiale L, Ruscito I, Abdul Halim T, Palaia I, Di Donato V, Pecorini F, Monti M, Muzii L, Panici PB.

Cell Mol Biol (Noisy-le-grand). 2015 Oct 30;61(6):44-61. Review.

PMID:
26518896
19.

Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.

Gasparri ML, Savone D, Besharat RA, Farooqi AA, Bellati F, Ruscito I, Panici PB, Papadia A.

Tumour Biol. 2016 Jan;37(1):71-5. doi: 10.1007/s13277-015-4299-9. Epub 2015 Oct 26. Review.

PMID:
26500096
20.

Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study.

Benedetti Panici P, Palaia I, Marchetti C, Ruscito I, Fischetti M, Musella A, Di Donato V, Perniola G, Vertechy L, Muzii L.

Oncology. 2015;89(2):103-10. doi: 10.1159/000381461. Epub 2015 Apr 29.

PMID:
25924602
21.

Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).

Marchetti C, Gasparri ML, Ruscito I, Palaia I, Perniola G, Carrone A, Farooqi AA, Pecorini F, Muzii L, Panici PB.

Crit Rev Oncol Hematol. 2015 Jun;94(3):302-10. doi: 10.1016/j.critrevonc.2015.02.001. Epub 2015 Mar 4. Review.

PMID:
25783620
22.

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).

Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.

Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.

PMID:
24889916
23.

Dualistic classification of epithelial ovarian cancer: surgical and survival outcomes in a large retrospective series.

Panici PB, Marchetti C, Salerno L, Musella A, Vertechy L, Palaia I, Perniola G, Ruscito I, Boni T, Angioli R, Muzii L.

Ann Surg Oncol. 2014 Sep;21(9):3036-41. doi: 10.1245/s10434-014-3714-6. Epub 2014 Apr 28.

PMID:
24770721
24.

Effects of unilateral ovariectomy on female fertility outcome.

Bellati F, Ruscito I, Gasparri ML, Antonilli M, Pernice M, Vallone C, Morano G, Chirletti P, Berloco PB, Panici PB.

Arch Gynecol Obstet. 2014 Aug;290(2):349-53. doi: 10.1007/s00404-014-3194-8. Epub 2014 Mar 11.

PMID:
24615568
25.

Monoclonal antibodies therapies for ovarian cancer.

Leone Roberti Maggiore U, Bellati F, Ruscito I, Gasparri ML, Alessandri F, Venturini PL, Ferrero S.

Expert Opin Biol Ther. 2013 May;13(5):739-64. doi: 10.1517/14712598.2013.767328. Epub 2013 Feb 4. Review.

PMID:
23373587
26.

Minimal invasive approaches for large ovarian cysts: a careful choice.

Bellati F, Gasparri ML, Ruscito I, Caccetta J, Benedetti Panici P.

Arch Gynecol Obstet. 2013 Mar;287(3):615-6. doi: 10.1007/s00404-012-2560-7. Epub 2012 Sep 18. No abstract available.

PMID:
22987258
27.

Past, present and future strategies of immunotherapy in gynecological malignancies.

Bellati F, Napoletano C, Ruscito I, Visconti V, Antonilli M, Gasparri ML, Zizzari IG, Rahimi H, Palaia I, Rughetti A, Benedetti Panici P, Nuti M.

Curr Mol Med. 2013 May;13(4):648-69.

PMID:
22934850
28.

Monoclonal antibodies in gynecological cancer: a critical point of view.

Bellati F, Napoletano C, Gasparri ML, Visconti V, Zizzari IG, Ruscito I, Caccetta J, Rughetti A, Benedetti-Panici P, Nuti M.

Clin Dev Immunol. 2011;2011:890758. doi: 10.1155/2011/890758. Epub 2011 Dec 26. Review.

29.

Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms.

Bellati F, Napoletano C, Gasparri ML, Ruscito I, Marchetti C, Pignata S, Tomao F, Benedetti Panici P, Nuti M.

Crit Rev Oncol Hematol. 2012 Jul;83(1):35-46. doi: 10.1016/j.critrevonc.2011.09.006. Epub 2011 Nov 4. Review.

PMID:
22056314
30.

Immune effects of trastuzumab.

Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J, Zizzari IG, Ruscito I, Rahimi H, Benedetti-Panici P, Rughetti A.

J Cancer. 2011;2:317-23. Epub 2011 May 25.

31.

Vaginal reconstruction with the Abbè-McIndoe technique: from dermal grafts to autologous in vitro cultured vaginal tissue transplant.

Panici PB, Ruscito I, Gasparri ML, Maffucci D, Marchese C, Bellati F.

Semin Reprod Med. 2011 Jan;29(1):45-54. doi: 10.1055/s-0030-1268703. Epub 2011 Feb 24. Review.

PMID:
21351049
32.

Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy.

Bellati F, Napoletano C, Ruscito I, Liberati M, Panici PB, Nuti M.

J Clin Oncol. 2010 Jul 20;28(21):e369-70; author reply e371. doi: 10.1200/JCO.2010.28.6922. Epub 2010 May 17. No abstract available.

PMID:
20479394
33.

Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review.

Bellati F, Napoletano C, Ruscito I, Pastore M, Pernice M, Antonilli M, Nuti M, Benedetti Panici P.

Invest New Drugs. 2010 Dec;28(6):887-94. doi: 10.1007/s10637-009-9351-4. Epub 2009 Nov 24. Review.

PMID:
19936983

Supplemental Content

Loading ...
Support Center